SyntheticGestalt and Enamine Partner to Create AI-Based Model for Drug Discovery
Shots:
- SyntheticGestalt and Enamine have collaborated for the creation of a suite of AI models to generate synthetically accessible, biologically active compounds with optimized physicochemical and ADME/Tox properties for effective compound discovery
- Under the collaboration, SyntheticGestalt will have access to Enamine’s REAL database, consisting of 38 billion molecules, to develop a pre-trained AI model for predicting physicochemical and ADME/Tox properties of compounds
- Enamine, through its in-house testing, will synthesize the chosen compounds within just 3-4wks. and provide quality pharmacological in vitro profiling data to expedite and shorten the discovery cycle
Ref: SyntheticGestalt | Image: SyntheticGestalt
Related News:- BioMap Collaborated with Sanofi to Co-Develop AI Modules to Advance Drug Discovery for Biotherapeutics Using BioMap’s AI Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
